CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 59
An inter-laboratory comparison study focused on the determination of total NNAL in human urine
NEWLAND K.(1); SCHERER M.(2); HECHT S.S.(3); TROUDE V.(4); PRASAD G.L.(5)
(1) Celerion Inc., Lincoln, NE, U.S.A.; (2) ABF GmbH, Planegg, Germany; (3) University of Minnesota Cancer Center, Minneapolis, MN, U.S.A.; (4) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (5) RAI Services Company, Winston-Salem, NC, U.S.A.
In an ongoing effort to fulfil the second objective of the CORESTA Biomarker Sub-Group, periodic inter-laboratory comparison studies have been performed to evaluate the consistency of the quantitation for various harmful or potentially harmful...